{"id":14799,"date":"2020-10-13T13:04:18","date_gmt":"2020-10-13T00:04:18","guid":{"rendered":"https:\/\/clladvocates.nz\/?p=14799"},"modified":"2020-10-13T13:04:18","modified_gmt":"2020-10-13T00:04:18","slug":"dr-davids-on-factors-to-inform-treatment-selection-in-cll","status":"publish","type":"post","link":"https:\/\/clladvocates.nz\/?p=14799","title":{"rendered":"Dr. Davids on Factors to Inform Treatment Selection in CLL"},"content":{"rendered":"

[vc_row row_height_percent=”0″ override_padding=”yes” h_padding=”2″ top_padding=”3″ bottom_padding=”3″ overlay_alpha=”50″ gutter_size=”3″ column_width_percent=”100″ shift_y=”0″ z_index=”0″][vc_column column_width_percent=”100″ gutter_size=”3″ overlay_alpha=”50″ shift_x=”0″ shift_y=”0″ shift_y_down=”0″ z_index=”0″ medium_width=”0″ mobile_width=”0″ width=”1\/1″][vc_custom_heading heading_semantic=”h1″ text_size=”h1″]<\/p>\n

Dr. Davids on Factors to Inform Treatment Selection in CLL<\/h1>\n

<\/h2>\n

[\/vc_custom_heading][vc_column_text]This article was originally published by OncLive<\/a><\/p>\n

\n
\n
\n
\n
\n

Matthew S. Davids, MD, MMSc, director of\u00a0clinical research in the\u00a0Lymphoma\u00a0Program and a medical oncologist with Dana-Farber Cancer Institute, as well as an assistant professor of medicine\u00a0at\u00a0Harvard Medical School, discusses factors to consider when selecting treatment for patients with chronic lymphocytic leukemia (CLL).<\/p>\n

When deciding which modality to select for patients with CLL, comorbidities must be considered, says Davids. For example, if there is a patient with significant cardiovascular disease, particularly if he\/she is on an anticoagulation medication for atrial fibrillation, BTK inhibitors may not be the optimal choice. For this patient, a venetoclax (Venclexta)-based regimen should be considered, according to Davids.<\/p>\n

On the other hand, if a patient has poor renal function and tumor lysis risk is a concern or if he\/she is older and has difficulty commuting to the medical center for frequent monitoring, then a BTK inhibitor is favored, says Davids. With this approach, there is less risk of tumor lysis and patients require less monitoring than they would with a venetoclax-based regimen, concludes Davids.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

 <\/p>\n

To continue reading this article on OncLive<\/a>[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Matthew S. Davids, MD, MMSc, discusses factors to consider when selecting treatment for patients with chronic lymphocytic leukemia<\/p>\n","protected":false},"author":1,"featured_media":14800,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[17,23],"tags":[],"class_list":["post-14799","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-featured","category-research"],"jetpack_featured_media_url":"https:\/\/clladvocates.nz\/wp-content\/uploads\/2020\/10\/Dr.-Davis.PNG-2.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/14799","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14799"}],"version-history":[{"count":1,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/14799\/revisions"}],"predecessor-version":[{"id":14801,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/14799\/revisions\/14801"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/media\/14800"}],"wp:attachment":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14799"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14799"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14799"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}